2025 Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma. Grace M. Ferri†, Cenk Yildirim†, Nhan V. Do, Mary T. Brophy, Nikhil C. Munshi, Camille V. Edwards‡, Nathanael R. Fillmore‡† Equal first authorship · ‡ Equal senior authorship EJHaem6(6), e70153 U.S. Veterans and VA Data Retrospective Cohort Study Multiple Myeloma Overall Survival Biomarkers
2025 Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma. Grace M. Ferri†, Cenk Yildirim†, Nhan V. Do, Mary Brophy, Joseph S. Park, Nikhil C. Munshi, Nathanael R. Fillmore‡, Camille V. Edwards‡† Equal first authorship · ‡ Equal senior authorship Blood Advances9(1), 78-88 U.S. Veterans and VA Data Retrospective Cohort Study Multiple Myeloma Overall Survival Biomarkers
2023 Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Jennifer La†, Clark DuMontier†, Hamza Hassan, Maya Abdallah, Camille Edwards, Karina Verma, Grace Ferri, Mayuri Dharne, Cenk Yildirim, June Corrigan, J. Michael Gaziano, Nhan V. Do, Mary T. Brophy, Jane A. Driver, Nikhil C. Munshi, Nathanael R. Fillmore† Equal first authorship Pharmacoepidemiology and Drug Safety32(5), 558-566 U.S. Veterans and VA Data Electronic Health Records Multiple Myeloma VA Cancer Registry Algorithm Validation
2023 Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Camille V. Edwards, Hamza Hassan, Cenk Yildirim, Grace Ferri, Karina P. Verma, Horwitz Mara E. Murray, Nathanael R. Fillmore, Nikhil C. Munshi Blood Advances7(4), 482-490 U.S. Veterans and VA Data Retrospective Cohort Study Multiple Myeloma Overall Survival Biomarkers
